Michael Buschle
Director/Board Member at VICORE PHARMA HOLDING AB
Michael Buschle active positions
| Companies | Position | Start | End |
|---|---|---|---|
| VICORE PHARMA HOLDING AB | Director/Board Member | 2022-12-31 | - |
HBM Partners AG
 HBM Partners AG Investment ManagersFinance HBM Partners AG (HBM-P) was established in 2001 as an independent provider of investment advisory services with headquarters in Zug, Switzerland. HBM-P's field of expertise comprises global human medicine, biotechnology, medical technology and related sectors. The firm primarily advises HBM BioVentures AG and HBM BioCapital via their Cayman Islands-based, wholly-owned subsidiary, HBM Partners (Cayman) Ltd., which acts as the investment manager for the HBM funds. They rely on the services of an external consultant to analyze investment opportunities in the US. | Private Equity Investor | 2016-12-31 | - |
Career history of Michael Buschle
Former positions of Michael Buschle
| Companies | Position | Start | End |
|---|---|---|---|
| Y-MABS THERAPEUTICS, INC. | Director/Board Member | 2017-09-30 | 2018-12-10 |
| Independent Dir/Board Member | 2017-09-30 | 2018-12-10 | |
| GLENMARK PHARMACEUTICALS LIMITED | Chief Tech/Sci/R&D Officer | 2012-01-22 | - |
Intercell AG
 Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | Chief Tech/Sci/R&D Officer | 1997-12-02 | - |
| Founder | 1997-12-02 | - |
Statistics
International
| Switzerland | 2 |
| Austria | 2 |
| India | 2 |
Operational
| Chief Tech/Sci/R&D Officer | 2 |
| Director/Board Member | 2 |
| Founder | 1 |
Sectoral
| Health Technology | 5 |
| Finance | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 3 |
|---|---|
| GLENMARK PHARMACEUTICALS LIMITED | Health Technology |
| VICORE PHARMA HOLDING AB | Health Technology |
| Y-MABS THERAPEUTICS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
HBM Partners AG
HBM Partners AG Investment ManagersFinance HBM Partners AG (HBM-P) was established in 2001 as an independent provider of investment advisory services with headquarters in Zug, Switzerland. HBM-P's field of expertise comprises global human medicine, biotechnology, medical technology and related sectors. The firm primarily advises HBM BioVentures AG and HBM BioCapital via their Cayman Islands-based, wholly-owned subsidiary, HBM Partners (Cayman) Ltd., which acts as the investment manager for the HBM funds. They rely on the services of an external consultant to analyze investment opportunities in the US. | Finance |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | Health Technology |
- Stock Market
- Insiders
- Michael Buschle
- Experience
